John Gnann to Treatment Outcome
This is a "connection" page, showing publications John Gnann has written about Treatment Outcome.
Connection Strength
0.211
-
Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease. Emerg Infect Dis. 2019 11; 25(11):2064-2073.
Score: 0.074
-
Impact of a rapid multiplex polymerase chain reaction blood culture identification technology on outcomes in patients with vancomycin-resistant Enterococcal bacteremia. Infect Dis (Lond). 2016 Oct; 48(10):732-7.
Score: 0.058
-
Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group. Antimicrob Agents Chemother. 1998 May; 42(5):1139-45.
Score: 0.017
-
Histoplasma meets Crohn's disease: a rare case of new-onset ascites. BMJ Case Rep. 2018 Apr 17; 2018.
Score: 0.017
-
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis. 2013 Nov 01; 208(9):1386-90.
Score: 0.012
-
Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis. 2009 Sep 15; 49(6):924-7.
Score: 0.009
-
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009 Apr; 142(3):209-217.
Score: 0.009
-
Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol. 2008 Oct; 43(2):190-5.
Score: 0.008
-
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004 Nov; 64(2):103-11.
Score: 0.007